The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...
Zacks.com on MSN13h
UBX Stock Down 29% on Mixed Results From Phase II Eye Disease StudyUNITY Biotechnology stock loses 29% as the mid-stage DME study of the lead candidate, UBX1325, fails to achieve statistical ...
We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we are going to look at where Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) ...
We recently published a list of 11 Best Extremely Profitable Stocks to Buy According to Analysts. In this article, we are ...
A team of scientists at the National Institutes of Health (NIH) has developed an eye drop that successfully slowed vision ...
A New Jersey-based biotech is looking to become the main character in the age-related macular degeneration field. | A New Jersey-based biotech is looking to become the main character in the ...
Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback